- Home
- SENEB vs CMMB Comparison
SENEB vs CMMB Comparison
Compare SENEB & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEB | CMMB |
|---|---|---|
| Founded | 1949 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 813.0M | 13.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SENEB | CMMB |
|---|---|---|
| Price | $114.50 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 517.0 | ★ 94.5K |
| Earning Date | 02-05-2026 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.79 | N/A |
| EPS | ★ 8.61 | N/A |
| Revenue | ★ $1,606,175,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.79 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $71.47 | $1.73 |
| 52 Week High | $124.94 | $9.84 |
Technical Indicators
Market Signals| Indicator | SENEB | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 55.85 | 28.76 |
| Support Level | $108.68 | $1.73 |
| Resistance Level | $115.00 | $2.24 |
| Average True Range (ATR) | 0.39 | 0.27 |
| MACD | -1.29 | -0.04 |
| Stochastic Oscillator | 35.79 | 14.42 |
Price Performance
Historical ComparisonAbout SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.